Loading clinical trials...
Loading clinical trials...
A Phase 3b, 42-day, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Nebulized Revefenacin and Nebulized Formoterol Fumarate (PERFOROMIST®) Administered in Sequence and as a Combined Solution in Subjects With Chronic Obstructive Pulmonary Disease
Conditions
Interventions
Revefenacin
Placebo
+1 more
Locations
12
United States
Theravance Biopharma Investigational Site
Miami, Florida, United States
Theravance Biopharma Investigational Site
Orlando, Florida, United States
Theravance Biopharma Investigational Site
Sarasota, Florida, United States
Theravance Biopharma Investigational Site
Tampa, Florida, United States
Theravance Biopharma Investigational Site
Saint Charles, Missouri, United States
Theravance Biopharma Investigational Site
Monroe, North Carolina, United States
Start Date
May 31, 2018
Primary Completion Date
September 25, 2018
Completion Date
September 25, 2018
Last Updated
February 24, 2022
NCT07307781
NCT07509606
NCT07451977
NCT07477600
NCT07082738
NCT07382258
Lead Sponsor
Mylan Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions